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TRANSLATIONAL RELEVANCE 
 
DNA vaccines combining human and heterologous HER2 sequences have been shown to 
be efficacious in transgenic mouse models, but no data are available in humans.  This 
work assessed the feasibility of using DNA coding for chimeric rat/human HER2 as a tool 
to overcome the tolerance of T cells from HER2-overexpressing cancer patients (CP). 
While dendritic cells from CP transfected with DNA plasmids coding for human HER2 do 
not activate T cells from CP, those transfected with chimeric rat/human HER2 induced 
antigen-specific perforin and IFN-γ-production by T cells, able to inhibit in vivo HER2+ 
tumor growth. The efficacy of chimeric plasmids relies on the ability to circumvent the 
suppressor effects by Treg cells and/or IL-10 and TGF-β1.  
These results provide for the first time the proof of concept that chimeric HER2 DNA 
plasmids can be used as effective vaccine for all HER2-overexpressing CP, with the 
advantage of being MHC independent. 
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ABSTRACT 
 
Purpose: Despite the great success of HER2 vaccine strategies in animal models, 
effective clinical results have not yet been obtained. We studied the feasibility of using 
DNA coding for chimeric rat/human HER2 as a tool to break the tolerance of T cells from 
HER2-overexpressing cancer patients. 
Experimental Design: Dendritic cells (DCs) generated from HER2-overexpressing breast 
(n=24) and pancreatic (n=14) cancer patients were transfected with DNA plasmids that 
express human HER2 or heterologous rat sequences in separate plasmids or as chimeric 
constructs encoding rat/human HER2 fusion proteins and used to activate autologous T 
cells. Activation was evaluated by IFN-γ ELISpot assay, perforin expression and ability to 
halt HER2+ tumor in vivo growth. 
Results: Specific sustained proliferation and IFN-γ production by cancer patients CD4 and 
CD8 T cells was observed after stimulation with autologous DC transfected with chimeric 
rat/human HER2-expressing plasmids. Instead, T cells from healthy donors (n=20) could 
be easily stimulated with autologous DCs transfected with any human, rat or chimeric 
rat/human HER2 portions. Chimeric HER-2-transfected DCs from HER2-overexpressing 
cancer patients were also able to induce a sustained T cell response that significantly 
impeded HER2+-tumor in vivo growth. The efficacy of chimeric plasmids in overcoming 
tolerance to HER2 relies on the ability to circumnvent suppressor effects by Treg cells 
and/or IL-10 and TGF-β1.  
Conclusions: These results provide the proof of concept that chimeric rat/human HER2 
DNA plasmids can be used as effective vaccines for all HER2-overexpressing cancer 
patients, independently of their MHC. 
 5
 
INTRODUCTION 
The ErbB-2 (neu in rat and HER2 in humans) tyrosine kinase receptor is an 
oncoantigen overexpressed by a variety of tumors (1). The driving role of HER2 in 
epithelial oncogenesis as well as its selective overexpression on malignant tissues makes 
it an ideal target for immunotherapy (2). Passive immunotherapy with monoclonal 
antibodies (mAb) such as trastuzumab, and receptor tyrosine kinase inhibitors, for 
example, lapatinib, are HER2-targeted therapies currently used for the treatment of HER2-
overexpressing breast cancers (3,4). Unfortunately, the therapeutic efficacy of both these 
therapies is abolished by primary and acquired tumor resistance, suggesting 
compensatory activity via alternative signaling pathways (5,6). Therefore, active 
immunotherapy against HER2 might provide an alternative strategy. 
Vaccination studies in mouse models using HER2/neu peptides have been 
successful in inhibiting tumor growth (7). In humans, however, whilst specific 
immunological responses have been elicited with HER2 peptides, effective clinical results 
have not yet been obtained (8). The principal reason for this is that HER2/neu is a self-
antigen and thus tolerogenic. Based on transgenic mouse models, it is now evident that 
this tolerogenicity causes deletion or inactivation of reactive high-avidity T cells against 
neu, thereby leading to self-tolerance (9). However low avidity self-specific T cells can be 
isolated from tolerant hosts and there are reports that such cells can be activated, 
expanded, and involved in antitumor responses (10). 
A lot of effort has been spent in trying to overcome self-tolerance towards tumor 
antigens, and considerable success has been achieved using heteroclitic or heterologous 
peptides (11-13). The use of heterologous peptides may also be advantageous in case of 
patients with HER2-overexpressing tumors due to the presence of critical amino acid 
substitutions that markedly improve their immunogenicity and induce activation of non-
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tolerized, cross-reactive and low affinity T cell clones. These, in turn, release cytokines 
that enhance immune recognition in a paracrine way and eventually activate autoreactive 
B cells. 
Chimeric vaccines containing both self human HER2 and heterologous rat neu DNA 
sequences induced a more potent cellular and humoral antitumor immunity than self 
sequence alone (14,15). However, no data on their potential efficacy in humans are 
currently available. Compared to peptide-based vaccines, DNA vaccination has been 
shown to be more advantageous (16). Indeed, DNA vaccines offer a precise strategy for 
delivering antigens to the immune system as they can be expressed on cell surfaces or, 
more commonly, as peptides in association with the MHC class I or II molecules, and their 
application is MHC  independent (for a review see 17,18). A first pilot clinical trial from 
Norell and colleagues demonstrated promising feasibility, safety and tolerability of 
vaccination with DNA coding for the full-length HER2 molecule in combination with 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-2 in 
patients with advanced breast cancer already receiving trastuzumab, but with limited 
clinical effects (19).  
 
Here we evaluated the feasibility of using DNA coding for chimeric rat/human HER2 
as a tool to counteract the tolerance of T cells from HER2-overexpressing cancer patients 
(CP).  We transfected monocyte-derived dendritic cells (DCs) from CP and healthy 
subjects (HS) with DNA plasmids coding for human, rat or chimeric rat/human HER2. Only 
DCs transfected with the chimeric plasmids were able to elicit a specific anti–HER2 
response by T cells from HER2-overexpressing CP. Their ability relies on the activation of 
a significant lower number of Treg cells and lower production of IL-10 and TGFβ1 that 
results in the rescue from HER2 tolerance.  
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In conclusion, these results provide the proof of concept that vaccination with 
chimeric rat/human HER2 DNA plasmids could be an effective therapeutic option for all 
patients with HER2+ tumors, with the advantage of being MHC-independent. 
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Materials and Methods 
Human specimens 
Human peripheral blood leukocytes (PBL) were isolated by Ficoll-Hypaque (Lonza) 
gradient centrifugation from heparinized venous blood of HS (n=20) provided by the local 
Blood Bank (Torino, Italy), and CP (n=38), not previously treated with radio- or chemo-
therapy. CP included patients with pancreatic adenocarcinoma (PDAC, n=14) or breast 
cancer (BC, n=24) recruited at the Centro Oncologico Ematologico Subalpino (COES), AO 
Città della Salute e della Scienza di Torino, Torino, Italy, with informed consent. Blood 
samples were immediately processed after drawing. Tumors from PDAC and BC patients 
were evaluated for HER2 positivity by immunohistochemistry (IHC). Only patients bearing 
HER2+ tumors that were classified as 3+ or 2+ by IHC were included in the study 
(Supplementary Table S1). Patients with a 0-1 IHC score (n=5) were used as a HER2 
negative control group (Supplementary Table S2). To determine human leukocyte antigen 
(HLA)-A2 positivity, PBL were incubated with anti-HLA-A2-PE mAb (clone BB7.2, BD 
Pharmingen) and expression was evaluated by flow cytometry. 
 
Cell cultures 
Monocyte-derived DC generation was conducted as previously described (20). 
TNF-α (50 ng/ml) and IL-1β (50 ng/ml, Peprotech) were added for the final 24 hours to 
induce DC maturation. CD14-depleted PBL were stored in liquid nitrogen until use. 
Thawed lymphocytes (>80% viability and >50% recovery) were cultured for 7 days with 
autologous transfected-DCs at  20:1 ratio in RPMI 1640 medium with 10% heat-
inactivated human serum AB (Lonza) at 2 x 106/ml. At day 3, one third of supernatants 
was collected and replaced with fresh complete medium plus IL-7 (10 ng/ml, PeproTech). 
The human pancreatic cancer cell line CF-PAC1 and the human ovarian carcinoma cell 
line SKOV-3-A2 (derived from SKOV-3 cells transduced by lentiviral vector with HLA-A2 
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gene), positive for the expression of HER2 and HLA-A2,  were cultured in DMEM medium 
(Invitrogen) with 10% FBS, penicillin G (50 U/ml) and streptomycin (50 µg/ml). T2 cells, a 
TAP-deficient B cell/T cell hybrid cell line that express HLA-A2 but lack antigenic peptides, 
were cultured in RPMI  1640 with 20% FBS. 
 
Plasmids and nucleofection 
Plasmid pVAX1 was the backbone for all the  DNA constructs used for transfection of 
DCs. All four plasmids code for the extracellular and transmembrane domains of HER2, 
as previously described (14). HuHuT codes for the fully human, and RRT  for the fully rat 
HER2 molecule. RHuT codes for the first two extracellular domains of rat HER2 and the 
remaining part of human HER2. Conversely, HuRT codes for the first two extracellular 
domains of human HER2 and the remaining part of rat HER2. Large-scale preparation of 
the plasmids was carried out using EndoFree Plasmid Maxi kits (Qiagen). Mature DCs 
were harvested on day 6 of culture, resuspended in 100μl of electroporation buffer (DC 
transfection kit, Amaxa, Lonza) and mixed with 5μg of plasmid DNA. Electroporation was 
performed using the Nucleofector program U-002 (Amaxa, Lonza). After electroporation, 
cells were immediately transferred to 2ml of complete media and cultured at 37°C. 
Efficiency of transfection was analyzed by flow cytometry after 6 hours following 
transfection. Transfected DCs were fixed, permeabilized, and stained with Ab4 or Ab5 
mAb (Calbiochem) followed by αmouse-PE (BD Biosciences). 
 
ELISpot assay 
After 7 days of co-culture, HLA-A2 restricted CD8+ T cell activation was detected by 
the IFNγ ELISPOT assay (BD Bioscience), following manifacturer’s instruction. T2 cells 
were loaded with 10 μg/ml of the HLA-A2+ immunodominant p369-377 E75 (KIFGSLAFL) 
or p654-662 GP2 (IISAVVGIL) peptides (PRIMM), for 6 hours at 37°C in serum-free 
medium. A total of 2.5 x 104 recovered T cells were seeded in 96-well ELISpot assay 
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plates (Millipore) at 10:1 ratio with E75 or GP2 loaded or unloaded T2 cells, in AIM-V 
medium (Invitrogen) for 24 hours. Spots were counted with a computer-assisted image 
analysis system, Transtec 1300 ELISpot Reader (AMI Bioline). The number of specific 
spots was calculated by subtracting the number of spots produced in the presence of 
unloaded T2 cells and spontaneously-produced spots.  
 
Flow cytometry 
PBL from HS and CP were stained with αCD14-APC (clone M5E2), αHLA-DR- 
PerCP (clone L243) (Biolegend) and αIL-4Rα-PE (clone 25463, R&D System) mAb to 
characterize the phenotype of CD14+ monocytes. Matched isotype controls were included 
for each sample. ΔMFI values were calculated by subtracting the fluorescence of control 
isotypes.  
FACS analysis of cell surface molecules on transfected DCs was carried out using the 
following mAb αCD80-PE (clone 2D10), αCD86-PE (clone IT2.2), αCD40-PE (BD 
Biosciences), αCD83-PE (clone HB15e) and αHLA-DR-PerCP (Biolegend).  
To detect Treg cells, PBL were stained with αCD4-PerCP (clone OKT4), αCD25-PE 
(clone BC96) (Biolegend) mAbs on the cell surface, treated with Fixation and 
Permeabilization buffer (eBioscience) and stained with αFoxp3-FITC (clone 236A/E7) 
mAb (eBioscience). 
To detect proliferating cells, PBL were stained with αCD4-PerCP and αCD8-PE (clone 
HIT8a) (Biolegend) mAbs on the cell surface, treated with Fixation and Permeabilization 
buffer and stained with αKi-67-APC (clone Ki67) mAb (Biolegend). 
For intracellular staining, 106 lymphocytes, recovered after 7 days-co-culture with 
transfected DCs, were resuspended in AIM-V, and restimulated with 1μg/ml coated αCD3 
(clone OKT3, Biolegend) and 1μg/ml soluble αCD28 (clone CD28.2, Biolegend) in the 
presence of 10μg/ml BrefeldinA (Sigma) at 37°C for 6 hours. Cells were washed twice and 
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incubated with αCD8-PE and αCD4-PerCP mAb (Biolegend) at 4°C for 30 min. After 
treatment with Fixation and Permeabilization buffer, cells were stained with αIFNγ-FITC 
(clone B27) and αperforin-APC (clone dG9) mAb (Biolegend) for 30 min at 4° C. Stained 
cells were acquired on a FACSCalibur flow cytometer equipped with CellQuest software 
(BD Biosciences). Cells were gated according to their light-scatter properties to exclude 
cell debris. 
 
In vitro cytotoxicity assay 
The 51Cr-release assay was performed at Effector-to-Target ratios of 50:1, 25:1, 
12:1 and 6:1. CF-PAC1 and SKOV-3-A2 target cells were labeled with 50μl 51Cr sodium 
chromate (PerkinElmer) in 5% CO2 for 1 hour at 37°C, washed twice and added to wells 
of 96-well plates (5 x 103 cells/well) with effector T cells recovered from 7-day co-cultures 
with transfected DCs. Assays were performed in triplicate in a final volume of 200μl of 
RPMI 1640 with 10% heat-inactivated certified FBS. After 4 hour incubation, 50μl of 
supernatants were collected on Lumaplate (PerkinElmer) and radioactivity was measured 
with a TopCount Scintillation Counter (Packard Biosciences). The percentage of specific 
lysis was calculated by ([experimental cpm - spontaneous cpm]/ [maximal cpm - 
spontaneous cpm]) x 100. Spontaneous release was always < 20% of maximal release.  
 
Apoptosis assay 
An Annexin V-FITC staining assay was performed to measure apoptosis in SKOV-
3-A2 cells, seeded in 24-well plates (5 x 104/well) and exposed to different doses of 
human rIFN-γ (Peprotech) or supernatants derived from DC-T cell co-cultures for 48 
hours. Cells were then collected by trypsinization, washed twice with PBS, and stained 
with Annexin V-FITC and PI (BD) for 15 min at room temperature. Positive cells were 
detected with flow cytometry. 
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Cytokine analysis 
Supernatants collected at day 3 of T cell-DC co-culture were  analyzed by ELISA 
for the presence of IL-10 and TGFβ (eBioscience) and IFN-γ (Biolegend) following the 
manufacturer’s instruction.  
 
Mice 
NOD-SCID IL2Rγnull (NSG; 6-week-old female) mice were bred under sterile 
conditions in our animal facilities. One x 106 SKOV-3-A2 tumor cells were injected 
subcutaneously (s.c.) in the left flank and tumor growth was measured twice a week with a 
caliper in two perpendicular diameters. Ten days after tumor challenge, 107 differently in 
vitro-activated T cells were injected in the tail vein. The appearance of a tumor diameter of 
5 mm was considered as death event. 
 
Immunohistochemistry 
 Tumors were harvested at necropsy, fixed in 10% formalin and dehydrated in 
70% ethanol. The fixed samples were then embedded in paraffin and four sequential serial 
sections/tumor were obtained. Sections were processed for IHC using αCD8 (clone 
C8/144B, Roche), αCD4 (clone 4B12) or αKi-67 (clone Mib-1) mAb which were applied 
using the Ultra BenchMark automated stainer (Ventana, Roche). Images were acquired 
using 20x  magnification and 4 fields/sample were pseudo-randomly selected. Percentage 
of positive nuclei were quantified by measuring the percentages of Ki-67+, CD8+, CD4+ 
cells, respectively, among the total mononuclear cells. 
 
Ethics statement 
The human studies were conducted according to the Declaration of Helsinki 
principles. Human investigations were performed after approval of the study by the 
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Scientific Ethics Committee of AO Città della Salute e della Scienza di Torino, Torino, Italy 
(Prot. No. 0085724 and 0012068). Written informed consent was received from each 
participant prior to inclusion in the study and specimens were de-identified prior to 
analysis. 
All animal studies were performed in accordance with EU and institutional guidelines 
approved by the Bioethics Committee for Animal Experimentation of the University of 
Torino, Italy (Prot. No. 4.2/2012).  
 
Statistical analysis  
Statistical analyses were performed using Prism 5.0 GraphPad Software and results 
are expressed as the mean ± SEM. One way ANOVA was performed, followed by 
Dunnett’s multiple comparison post-test when needed. Kaplan-Mayer survival curves were 
evaluated with both the Log Rank Mantel-Cox and the Gehan-Breslow-Wilcoxon test. Only 
p values <0.05 were considered to be significant. 
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RESULTS 
 
 
Only chimeric RHuT-DCs are able to elicit a specific anti-HER2 response by CD8 T 
cells from HER2-overexpressing CP.   
Mature DCs (mDCs) were generated in vitro from CD14+ monocytes of HS and CP 
(Supplementary Table S1), as previously reported (26). CD14+ cells derived from CP 
express higher amounts of IL-4Rα and lower levels of HLA-DR molecules compared to 
those from HS (Supplementary Fig. S1A). These data are in line with current notions 
indicating an expansion of a monocyte population with a myeloid-derived suppressor cell-
like phenotype that correlates with tumor growth (21). 
Despite these differences in their precursors, mDCs from both CP and HS expressed 
similarly high levels of the maturation markers and co-stimulatory molecules CD83, CD80, 
CD86, CD40 and HLA-DR ( Supplementary Fig. S1, B and C).  
Nucleofection of the four  plasmids self HuHuT, chimeric HuRT and RHuT, heterologous 
RRT always gave a range of 35-45% positive mDCs from both HS and CP 
(Supplementary. Fig. S2A), thus showing high reproducibility (Supplementary Fig. S2B). 
DCs transfected with pVAX1 plasmid (empty-DCs) were used as control. These results 
indicate that mDCs generated from CP display similar features and potential stimulatory 
capacity as those from HS. 
To assess the ability of self versus heterologous and chimeric DNA plasmids to 
induce a specific anti-HER2 CD8 T cell response, mDCs generated from HS and HER2-
overexpressing CP were transfected with the different plasmids specified above, and used 
to stimulate autologous T cells. After 7 days of co-culture, CD8 T cells from HS stimulated 
with self HuHuT- or chimeric HuRT- and RHuT-DCs displayed higher proliferative ability 
compared to those stimulated with empty-DCs, while heterologous RRT-DCs had no effect 
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(Fig. 1, A and B). By contrast, only chimeric RHuT-DCs induced proliferation of CD8 T 
cells from HER2-overexpressing CP (Fig. 2, A and B).  
Activated T cells were then restimulated with anti-CD3/anti-CD28 mAb and analyzed for 
IFN-γ and perforin expression.  A similar increase in the percentage of IFN-γ-producing 
CD8 T cells was obtained from co-culture of HS T cells with HuHuT- or chimeric HuRT- 
and RHuT-DCs compared to those with empty-DCs. Chimeric RuHT-DCs also triggered an 
increase in the expression of perforin (Fig. 1C). By contrast, only chimeric RHuT-DCs from 
HER2-overexpressing CP led to the expression of both IFN-γ and perforin by CD8 T cells; 
transfection with the other plasmids had no effect (Fig. 2C). The concomitant expression of 
IFN-γ and perforin in CD8 T cells implies their potential cytotoxic ability. 
The specificity of the CD8 T cell response against human HER2 was assessed by 
IFN-γ ELISpot assay. Lymphocytes from HLA-A2+ HS and CP recovered from the different 
co-cultures were stimulated with HLA-A2+ matched T2 cells loaded with immunodominant 
HER2-derived E75 (22) and GP2 (23) peptides. Compared to control empty-DCs, self 
HuHuT- and chimeric RHuT-DCs from HS were able to activate a significant number of 
IFN-γ-releasing T  cells in response to both peptides, while chimeric HuRT-DCs only in 
response to the GP2 peptide (Fig. 1D). By contrast, in CP, only chimeric RHuT-DCs were 
able to elicit peptide-specific IFN-γ production (Fig. 2D).  
Moreover, T cells activated by HuHuT-, HuRT- and RHuT-DCs from HS were able 
to kill HER2+ CF-PAC1 and SKOV-3-A2 tumor cells, as evaluated by a 4-hour 51Cr release 
assay (Fig. 1E). In T cells from HER2-overexpressing CP, only stimulation with the 
chimeric RHuT-DCs led to destruction of the tumor cells (Fig. 2E). 
Overall, these data indicate that DCs transfected with the chimeric plasmid RHuT 
were able to overcome tolerance to human HER2 of T cells from HER2-overexpressing 
CP and to induce a specific anti-HER2 CD8 cytotoxic response. 
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Chimeric HER2-transfected DCs from HER2-overexpressing CP elicit a Th1 
response 
In order to activate a stronger and longer-lasting antitumor response, vaccines must 
not only elicit  cytotoxic CD8 T cells but also  Th1 cells (24).  We first evaluated CD4 T 
cells in  in vitro proliferation. All self HuHuT-, chimeric HuRT- and RHuT- and heterologous 
RRT-DCs from HS triggered proliferation of autologous CD4 T cells to similar levels, as 
evaluated by Ki--67 staining (Fig. 3, A and B). Conversely, only chimeric HuRT- and 
RHuT-DCs from HER2-overexpressing CP stimulated a significantly higher proliferation of 
CD4+ T cells compared to empty-DCs, while heterologous RRT- and self HuHuT-DCs had 
no effect (Fig. 3, A and C). After 7 days of co-culture, activated T cells were restimulated 
with anti-CD3/CD28 mAb and analyzed for IFN-γ expression. Only chimeric HuRT- and 
RHuT-DCs from CP triggered a higher percentage of IFN-γ-producing CD4 T cells 
compared to empty-DCs (Fig. 3E). By contrast, DCs from HS transfected with the different 
self HuHuT, chimeric HuRT and RHuT and heterologous RRT plasmids all resulted in a 
similar increase in IFN-γ-producing CD4 T cells compared to empty-DCs (Fig. 3D). 
This evidence demonstrates that DCs from HER-overexpressing CP transfected 
with both the chimeric HER2 plasmids are able to trigger a Th1 response. 
 
T cells from HER2-overexpressing CP activated by chimeric HuRT- and RHuT-DCs 
impede HER2+ tumor growth in vivo.    
Next we evaluated whether T cells from HER2-overexpressing CP activated in vitro, 
with self or chimeric HER-2-transfected DCs, were able to counteract growth of HER2+  
cancer cells in vivo, in a therapeutic setting. Immunodeficient NSG mice were challenged 
subcutaneously in the left flank with 106 SKOV-3-A2 cells. After 10 days, when mice were 
already displaying established palpable tumors, they were injected with 107 in vitro-
activated lymphocytes in the tail vein.  
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T cells activated by chimeric HuRT- and RHuT-DCs were able to delay tumor growth, 
whilst mice treated with T cells activated by self HuHuT-DCs developed tumors with the 
same kinetics as mice receiving T cells activated by empty-DCs or PBS only (Fig. 4A). 
Moreover, T cells from co-cultures with HuRT- and RHuT-DCs significantly improved 
overall survival (Fig. 4B). After 50 days following tumor challenge, 57% and 20% of mice 
injected with T cells activated by chimeric RHuT- and HuRT-DCs, respectively, were still 
alive, compared  to 0% of mice injected with T cells activated by empty- or self HuHuT-
DCs. 
Lower tumor growth was consistent with a lower Ki-67 expression in tumors from 
mice injected with T cells recovered from co-cultures with  RHuT- and HuRT-DCs (% of Ki-
67+ cells 32,3+2.6 and 37.6+5.8, respectively, versus 63.9+1.5 in tumors from mice 
injected with T cells from co-cultures with HuHuT-DCs), and further supports the notion 
that these T cells are able to impede tumor growth (Fig. 4C). Moreover, 
immunohistochemical analysis showed that tumors from mice injected with T cells from co-
cultures with RHuT-DCs  displayed high levels of CD4 and CD8 infiltration throughout the 
tumor mass, while those receiving T cells from co-cultures with HuRT-DCs displayed only 
high amounts of CD4, concentrated at the periphery of the tumor growing area (Fig. 4C), 
suggesting a key role of these cells in counteracting tumor growth. Low or no T cell 
infiltration was evident in tumors from the other treated  groups. 
Overall these data demonstrated that DCs transfected with chimeric RHuT and 
HuRT plasmids activate T cells  able to impede the growth of established tumors in vivo, 
via different mechanisms, either mediated by both CD8 and CD4 or only CD4 T cells, 
respectively. CD4 T cell-mediated inhibition of tumor growth is clearly independent of 
perforin, while cytokine secretion, such as IFN-γ, contributes to the impairment of tumor 
growth (25). Higher levels of IFN-γ were indeed detected in supernatants derived from co-
cultures with chimeric HuRT- and RHuT-DCs compared to the other co-cultures with self 
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or heterologous HER2 (Fig. 5A), consistent with the higher intracytoplasmatic expression 
of IFN-γ in both CD4 and CD8 T cells (Fig. 2C and 3E).  
To verify the role of IFN-γ in the inhibition of in vivo tumor growth, SKOV-3-A2 tumor 
cells were cultured for 48 hours with supernatants derived from the different co-cultures. 
Supernatants from both chimeric RHuT- and HuRT-DCs co-cultures induced higher 
percentages of apoptotic cells in comparison to those from empty-DC co-cultures (Fig. 5, B 
and C). The addition of IFN-γ neutralizing mAb to the supernatants abrogated this effect. 
Moreover, when SKOV-3-A2 cells were cultured for 48 hours with increasing 
concentrations of recombinant human IFN-γ, from 0.5 to 8 ng/ml, a dose response 
apoptotic induction was observed (Fig. 5 D). 
These results suggest that the antitumor response elicited by chimeric RHuT- and HuRT-
DCs may be in part mediated by IFN-γ. However, the more potent antitumor response 
induced by co-culture with RHuT-DCs seems to also involve perforin-expressing CD8 T 
cells. 
 
The inability of self HuHuT-DCs to activate T cells from HER2-overexpressing CP 
against HER2 is dependent on IL-10 and TGFβ1 production.  
Many publications have already reported an expansion of regulatory cells in the 
peripheral blood of cancer patients (26,27). As we stimulated T cells with transfected DCs, 
it is conceivable that regulatory cells, already expanded in CP (Supplementary Fig. S3A), 
could also be activated and expanded (28). However, we did not observe any differences 
in the percentage of CD4+CD25+FoxP3+ Treg cells after 7 days of co-culture with 
autologous DCs transfected with the four different plasmids (Supplementary Fig. S3B). 
Therefore we evaluated the ability of Treg cells purified from the PBL of HER2-
overexpressing CP, and cultured with differently transfected DCs, to suppress the 
activation of CD4+CD25- autologous T cells. Treg cells co-cultured with HuHuT-DCs 
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displayed a significantly higher suppressive activity compared to those with empty-DCs 
(Supplementary Fig. S3C). 
The inability of DCs transfected with self HuHuT to induce an effective response of 
Th1 and CD8 T cells from HER2+ CP could be attributed to soluble factors released by 
immune cells, namely IL-10 (29) and TGFβ1 (30). We evaluated the presence of these 
cytokines in the supernatants of co-cultures. While comparably low levels of IL-10 were 
detected in co-cultures with empty-, self HuHuT-, chimeric RHuT- and heterologous RRT-
DCs from HS, self HuHuT-DCs from HER2-overexpressing CP induced a significantly 
higher production of IL-10 compared to empty-DCs. Interestingly, chimeric HuRT-DCs 
from both HS and CP stimulated high levels of IL-10 secretion (Fig. 6A). In cells from HS, 
DCs transfected with all four DNA plasmids induced the production of similar levels of 
TGFβ1, but in cells from CP, self HuHuT-DCs stimulated higher secretion of TGFβ1 
compared to the empty-DCs (Fig. 6B). In conclusion, an increase of both IL-10 and TGFβ1 
were detected in co-cultures of T cells from HER2-overexpressing CP with HuHuT-DCs.   
To assess whether IL-10 and TGFβ1 production had a role in inhibiting the CD8 and 
CD4 T cell response against human HER2, lymphocytes from CP were activated with self 
HuHuT-DCs in the presence of anti-IL-10 and/or anti-TGFβ1 neutralizing mAb. 
Neutralization of both cytokines restored the ability of HuHuT-DCs to induce not only IFN-γ 
and perforin expression by CD8 T cells (Fig. 6C), but also a specific response against the 
immunodominant E75 and GP2 peptides (Fig. 6D) as well as RHuT-DCs (Fig. 2D). In 
addition, the ability of CD4 T cells to produce IFN-γ was also rescued (Fig. 6E). Overall, 
these data strongly suggest that the presentation of self HER2 could promote suppressive 
mechanisms, such as IL-10 and TGFβ1 production that impair antigen-specific CD8 and 
CD4 T cell activation. 
Based on our results we hypothesized that, in HER2-overexpressing CP,  HER2- 
specific regulatory cells are expanded and that self HuHuT-DCs could stimulate these cells 
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to produce IL-10 and TGF-β1. To clarify this point, DCs  generated from CP with breast 
and pancreatic adenocarcinoma negative for HER2 expression, (Supplementary Table S2) 
were transfected and co-cultured with autologous lymphocytes. In this case self HuHuT-
DCs did not suppress the production of IFN-γ and perforin by CD8 T cells, (Supplementary 
Fig. S4A) similarly to what was observed in co-cultures from HS (Fig. 1A). Moreover, self 
HuHuT-DCs were also able to expand CD4 T cells expressing IFN-γ, as for chimeric 
HuRT- and RHuT-DCs and heterologous RRT-DCs (Supplementary Fig. S4B). Notably, 
self HuHuT-DCs from CP bearing HER2-negative tumors did not induce suppressive 
mechanisms such as IL-10 (Supplementary Fig. S4C) and TGFβ1 production 
(Supplementary Fig. S4D). 
These data indicate an increase of HER2-specific regulatory cells in HER2-
overexpressing CP as a result of antigen overexpression that can be restimulated by the 
total self sequence of HER2. 
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DISCUSSION 
 
In the current study, we demonstrated, for the first time, that DNA plasmids coding 
for chimeric rat/human HER2 are able to elicit an effective immune response by T cells 
from HER2-overexpressing CP and efficiently circumvent tolerance mechanisms. No T cell 
response against HER2 was induced by autologous DCs transfected with DNA plasmids 
coding for self or fully heterologous HER2. By contrast, both self HuHuT- and chimeric 
RHuT-DCs from HS, as well as those from patients bearing HER2-negative tumors, in 
which there are no HER2-specific negative regulatory mechanisms, showed a similar 
induction of HER2-specific CD8 T cell response.  
Anti-HER2 vaccines consisting of MHC class I restricted peptides demonstrated the ability 
to elicit immunological responses and some clinical benefits in disease-free breast cancer 
patients (31). However, the efficacy of the immune response required for antigen-specific 
tumor inhibition depends not only on correct antigen presentation by DCs and activation of 
cytotoxic CD8 T cells, but also on the magnitude of CD4 Th reactivity (32,33). Indeed, 
vaccination of cancer patients with both Th epitopes and MHC class I binding motifs 
elicited enhanced HER2 peptide-specific CTL expansion and provided durable responses 
detectable more than 1 year after the final vaccination (34). 
Nevertheless, HLA restriction limits the potential number of patients who can 
receive these vaccines, and the use of DNA plasmids coding for tumor antigens has 
therefore been shown to be advantageous (16). Vaccines able to induce both CD8 and 
CD4 responses, and hence CTL and humoral immunity, are considered better than 
vaccines able to induce just one response.  
Here we demonstrated that different combinations of rat/ human HER2 sequences induce 
anti-HER2 immune responses through different mechanisms, suggesting that the position 
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of heterologous moieties is determinant for overcoming tolerance to HER2 by CD4 and 
CD8 T cells from HER2-overexpressing CP.  
CD4 Th cells provide critical signals for priming and maintenance of effector T cells (32). 
Moreover, CD4+ Th1 cells can directly mediate tumor inhibition through cytokine secretion, 
such as IFN-γ, which may induce cytotoxic and cytostatic effects on tumor cells (35) as 
well as their senescence (36). Indeed, chimeric-transfected DCs from HER2-
overexpressing CP elicited enhanced T cell IFN-γ secretion that induced apoptosis of 
cancer cells. 
In recent years, a number of reports have identified Treg cells specific for a range of 
different tumor antigens in human cancer, including HER2 (37). The presence of these 
cells in cancer patients raises serious concerns about the potential of cancer vaccines to 
expand not only effector but also regulatory cells. Many cancer vaccines have failed to 
induce significant clinical benefits, despite the induction of seemingly potent tumor antigen-
specific responses (38,39). 
Vaccination with a xenogeneic antigen has been reported to be effective in overcoming the 
immunological tolerance to self proteins (40). Results obtained from transgenic mouse 
models demonstrated that vaccination with DNA plasmids coding for xenogeneic HER2 
elicited a strong immunological response without cross-reaction (13). Chimeric rat/human 
HER2 plasmids were most effective in blunting immune tolerance to both rat and human 
HER2, suggesting that the presence of heterologous regions enhances immunogenicity 
against the antigen (14,15). Thus, the self sequence ensures the specificity of the immune 
response, while the xenogeneic part circumvents immune tolerance. 
Increased levels of Treg cells were observed both in our cohort of patients, and in patients 
with different malignancies, and are associated with worse outcomes (41). Treg cells 
inhibit primary T-cell activation and are paradoxically expanded by tumor vaccines coding 
 23
for self sequences (42-45). Indeed, we show that HuHuT-DCs did not affect Treg 
expansion, but elicited their stronger suppressive ability. It is possible that DCs transfected 
with self HuHuT presented the immunodominant peptides recognized by Treg cells. By 
contrast, the combination of heterologous sequences, as present in chimeric RHuT and 
HuRT, counteracts this phenomenon by presenting additional non-self peptides, activating 
new Th cells able to release cytokines that rescue bystander anergic T and B lymphocytes  
The weakly-induced suppressive machinery, such as IL-10 and TGFβ1 secretion, seemed 
to represent the success of chimeric variants in activating antitumor responses. We 
observed a higher production of the suppressive cytokines IL-10 and TGFβ1 in HuHuT-DC 
co-cultures from HER2-overexpressing CP, but not from HER2 negative CP or HS. 
Moreover, when we blocked the effects of these cytokines by adding neutralizing 
antibodies, the ability of self-sequences to activate both CD4 and CD8 responses was 
restored. These results further confirm the key role of IL-10 (46) and TGFβ1 (47) in 
suppressing an antigen-specific CD8 T cell response in cancer patients and in inhibiting 
anti-tumor immune responses. Whether these cytokines affect the stimulatory capacity of 
DCs, or directly affect antigen-specific T cell activation still needs to be determined.  
Our results provide the proof of concept that chimeric rat/human HER2 DNA constructs 
are able to overcome tolerance of T cells from HER2-overexpressing CP and elicit an 
efficient anti-HER2 response that avoids the activation of regulatory mechanisms. 
Therefore, chimeric HER2 DNA plasmids, or DCs transfected with these plasmids, could 
represent a novel therapeutic approach for all patients with HER2-overexpressing cancer, 
and introduce a new concept for designing anti-cancer vaccines. 
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LEGENDS TO FIGURES 
Figure 1. HuHuT-, HuRT- and RHuT-DCs from HS elicit anti-HER2 CD8 response. (A) 
Representative expression of Ki-67 on CD8+ T cells after 7 day of co-culture with empty- 
(), HuHuT- (), HuRT- (), RHuT- () or RRT-DCs (). Results from one of four 
experiments are shown. (B) Percentage of Ki-67+ on CD8+ T gated cells from 4 HS. * 
p<0.05 compared to empty-DCs.  (C) IFN-γ and perforins intracellular staining of CD8 T 
cells. After 7 day of co-culture T cells were restimulated with αCD3/CD28 mAb (1μg/ml). 
Graphs show percentage of IFN-γ+ (left panel) and perforins+ (right panel) cells in CD8+ T 
gated cells from eight HS. *p<0.05,  ** p<0.001 compared to empty-DCs. (D) IFN-γ 
ELISPOT assay performed after 7 days of culture with transfected DCs from HS (n=17). 
IFN-γ release was evaluated in response to T2 cells pulsed with E75 or GP2 peptides. 
Values of peptide-specific spots were calculated  by subtracting the number of spots 
against unloaded T2 from the number of spots against peptide-loaded T2. ** p<0.001, *** 
p<0.0001 compared  to empty-DCs. (E) Cytotoxicity assay. After 7 day co-cultures, 
recovered T cells were tested in a 4 h 51Cr release assay at different Effector:Target ratios 
against CF-PAC1 or SKOV-3-A2 cells. Percentage of specific lysis was determined as 
described in Methods. * p<0.05, ** p<0.001, *** p<0.0001 compared  to empty-DCs. 
Figure 2. RHuT-DCs from HER2-overexpressing CP elicit anti-HER2 CD8 T cell 
response. (A) Representative expression of Ki-67 on CD8+ T cells after 7 day of co-
culture with empty- (), HuHuT- (), HuRT- (), RHuT- () or RRT-DCs (). Results 
from one of six experiments are shown (B) Percentage of Ki-67+ on CD8+ T gated cells 
from six HER2-overexpressing CP. * p<0.05. compared to empty-DCs  (C) Percentage of 
IFNγ+ (left panel) and perforins+ (right panel) on CD8+ T gated cells from HER2-
overexpressing CP (n=12). *** p<0.0001 compared to empty-DCs. (D) IFN-γ ELISPOT 
assay performed after 7 days  co-culture with transfected DCs from HER2-overexpressing 
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CP (n=13). IFN-γ release was evaluated in response to T2 cells pulsed with E75 or GP2 
peptides. *** p<0.0001 compared to empty-DCs. (E) 51Cr release assay against CF-PAC1 
or SKOV-3-A2 cells. ** p<0.001, *** p<0.0001 compared  to empty-DCs. 
Figure 3. Chimeric HuRT- RHuT-DCs from HER2-overexpressing CP elicit a Th1 
response.  Proliferation and IFN-γ expression of CD4+ T cells after 7 day  co-culture with 
transfected DCs. (A) Representative expression of Ki-67 on CD4+ T gated cells of HS 
(upper row) and HER2-overexpressing CP (lower row). Graphs show percentage of Ki-67+ 
gated on CD4+ T cells from four HS (B) and seven HER2-overexpressing CP (C). IFN-γ-
intracellular staining of CD4 T cells. After 7 day of co-cultures with transfected DCs, 
recovered T cells were restimulated with αCD3/CD28 mAb (1μg/ml). Graphs show 
percentage of IFNγ+ on CD4+ T gated cells from five HS (D) and eight HER2-
overexpressing CP (E). * p<0.05, ** p<0.001, *** p<0.0001 compared to empty-DCs. 
Figure 4. T cells from HER2-overexpressing CP activated in vitro with HuRT- and 
RHuT-DCs are able to inhibit HER2+ tumor growth. One x 106 SKOV-3-A2 cells were 
injected s.c. in the left flank of NSG mice. Mice were injected i.v. with 107 in vitro activated 
T cells with empty- (, n=5), HuHuT- (, n=5), HuRT- (, n=5), RHuT-DCs (, n=7) or 
PBS (, n=12) at day 10 after tumor challenge. (A) Tumor growth was monitored weekly 
and expressed as tumor volume. ** p<0.001, *** p<0.0001 (B) Kaplan-Meier survival 
analysis of  untreated and treated mice. Tumor diameter of 5 mm was considered as lethal 
event. * p<0.05, ** p<0.001 compared to untreated group. (C) Representative 
immunohystochemical staining of tumor sections from mice injected with T cells recovered 
from co-cultures  with  transfected DCs, for Ki-67 (upper row), CD8 (middle row) or CD4 
(lower row) expression. The percentage of positive cells on total cells evaluated in each 
single mouse is reported as mean±SEM (n=3 per group). * p<0.05, ** p<0.001, *** 
p<0.0001 compared  to empty-DCs.  
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Figure 5. HuRT- and RHuT-DCs from HER2-overexpressing CP elicit enhanced IFN-γ 
production. (A) IFN-γ production analyzed by ELISA on supernatants of co-cultures of T 
cells from CP with autologous transfected DCs (n=15) collected at day 3. *** p<0.0001. 
compared to empty-DCs. (B) Representative AnnexinV/PI assay of SKOV-3-A2 cells 
cultured for 48 h with supernatants derived from DC co-cultures. (C) Graphs show the 
percentage of AnnexinV+PI+ SKOV-3-A2 cells cultured for 48 h with supernatants derived 
from co-cultures of three different CP. ** p<0.001 compared to empty-DCs. (D) 
AnnexinV/PI assay of SKOV-3-A2 cells cultured for 48 h with indicated concentration of 
human rIFN-γ. 
Figure 6. IL-10 and TGFβ1 neutralization both restore the ability of HuHuT-DCs to 
activate anti-HER2 T cell responses from HER2-overexpressing CP. IL-10 (A) and 
TGFβ1 (B) production analyzed by ELISA on supernatants from co-cultures of T cells from 
HS (white dots, n=9 ) and CP (grey dots, n=13 ) with autologous transfected DCs, 
collected at day 3. * P<0.05, *** P<0.0001 compared to empty-DCs.  (C) and (D) DCs from 
HER2-overexpressing CP were transfected with HuHuT () or empty plasmid (), and 
cultured with autologous T cells in the presence of neutralizing mAb for IL-10 and/or 
TGFβ1 or control isotypes. (C) Percentage of IFNγ+ and perforin+ cells in CD8+ T gated 
cells (left and right panels). * P<0.05. compared to empty-DCs (D) IFNγ response 
evaluated by ELISpot assay in response to T2 cells loaded with E75 and GP2 peptides 
was compared to that elicited by RHuT-DCs. * P<0.05, ** P<0.001 compared to empty-
DCs. (E) Percentage of IFNγ+ cells in CD4+ T gated cells. * P<0.05 compared to empty-
DCs. 
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